John Hoekman - 20 Jul 2021 Form 4 Insider Report for IMPEL NEUROPHARMA INC

Role
Chief Scientific Officer
Signature
/s/ John Leaman, M.D. as attorney-in-fact
Issuer symbol
N/A
Transactions as of
20 Jul 2021
Net transactions value
$0
Form type
4
Filing time
26 Jul 2021, 17:58:54 UTC
Previous filing
07 Jun 2021
Next filing
23 Dec 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMPL Stock Option (right to buy) Award $0 +50,000 $0.000000 50,000 20 Jul 2021 Common Stock 50,000 $12.16 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 2.0833% of the total shares on August 22, 2021 and then 2.0833% of the total shares vests monthly thereafter, with 100% of the total shares vested and exercisable on July 22, 2025, subject to the reporting person's provision of service to the issuer on each vesting date.